Fundraising Fox
/Companies
Sign in

Trestle Biotherapeutics

YC W21

San Diego, US · Founded 2020 · 2 employees · 12 known investors

Find your way into Trestle Biotherapeutics

Sign up to see every warm intro you have to Trestle Biotherapeutics

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Trestle Biotherapeutics team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Trestle Biotherapeutics develops bioengineered implantable tissues designed to treat end-stage renal disease, aiming to get patients off dialysis and eventually provide replacement organs. The company uses stem cell biology, biofabrication, and 3D bioprinting technologies to create functional kidney tissue for patients with kidney failure.

BiotechDeep TechHealthtechMedical DevicesUnited States of AmericaAmerica / Canada

Founders & leadership· Y Combinator alumni (W21)

Trestle Biotherapeutics was founded in 2020 by Ben Shepherd, Alice Chen, and Alice Chen, PhD.

BSBen Shepherd
Ben ShepherdCo-founder & CEOBen Shepherd is a vascular biologist and tissue engineer who previously held an academic position at Yale School of Medicine before spending over a decade in industry developing research teams focused on 3D bioprinting and biofabrication technologies for tissue engineering applications.
ACAlice Chen
Alice ChenCo-Founder & CSOAlice Chen has 20+ years of research experience in developmental biology, stem cell biology, and tissue engineering. She founded Trestle Biotherapeutics to develop therapeutic tissue for chronic kidney disease treatment.
ACAlice Chen, PhD
Alice Chen, PhDCo-founder and Chief Scientific OfficerChen spent four years at Organovo Holdings, where she rose from Associate Director of R&D for tissue applications to Director of Research and Preclinical Development, and previously led cell reprogramming at ESI BIO, a division of BioTime, and R&D work in cellular differentiation and reprogramming services at Stemgent. She completed a postdoctoral fellowship at the Harvard Stem Cell Institute.
BS
Ben Shepherd, PhDCo-Founder and Chief Executive Officer

Investors · 12

Black Mountain Ventueslisted by Black Mountain Ventues

How we know: Black Mountain Ventues's portfolio page · Not right? Tell us

C3 Ventureslisted by C3 VenturesLos Angeles

How we know: C3 Ventures's portfolio page · Not right? Tell us

Draper Associateslisted by Draper AssociatesSan Mateo · $500K – $5M
Acequia Capital (AceCap)reportedSeattle · $100K – $5M

How we know: Y Combinator's founder network · Not right? Tell us

Agrolimen Venturesreported

How we know: Y Combinator's founder network · Not right? Tell us

Asymmetry VenturesreportedRichmond · $125K – $500K

How we know: Y Combinator's founder network · Not right? Tell us

Axial VCreportedSan Francisco · $100K – $5M

How we know: the VCSheet dataset · open dataset · 5k.vc investor directory · Y Combinator's founder network · Not right? Tell us

Black Mountain Investment GroupreportedNew York City

How we know: Y Combinator's founder network · Not right? Tell us

FAST — by GETTYLABreportedSan Francisco · $100K

How we know: Y Combinator's founder network · Not right? Tell us

Formic VenturesreportedSan Francisco

How we know: Y Combinator's founder network · Not right? Tell us

Harvard Management CompanyreportedAllston

How we know: Y Combinator's founder network · Not right? Tell us

Related companies · 7

Kern SystemsKern Systems develops a cold data storage platform using synthetic DNA molecules and enzymes to archive data with superior density, durability, and energy efficiency compared to traditional storage technologies. The platform targets the growing market for long-term archival storage of rarely-accessed unstructured data.
Medium BiosciencesMedium Bio engineers customized proteins using AI and protein design to create affinity reagents for research teams and diagnostic developers. The company accelerates molecular tool development from design to experimental validation within weeks.
FrekilFrekil automates real-world evidence generation for pharmaceutical and healthcare research, using AI agents to build patient cohorts, design studies, and generate statistical analyses from existing clinical data. The platform enables epidemiological workflows across drug safety monitoring, comparative effectiveness, label expansion, and trial feasibility assessments.
Fortis Life SciencesFortis Life Sciences develops and manufactures Bethyl-branded ELISA kits and related reagents, buffers, and antibodies for detecting target proteins in research and diagnostic applications. The kits cover human and veterinary targets and are made in the USA using the company's own antibodies.
AlixiaAlixia develops therapeutics targeting tumor ecosystems to address cancer drug resistance and age-related diseases. The company integrates biology, biophysics, and computational chemistry to design compounds that disrupt metabolic and inflammatory triggers in multiple cell types within the tumor microenvironment.
Krystal BiotechKrystal Biotech discovers, develops, and commercializes genetic medicines, including gene therapy programs for rare diseases such as dermatological conditions. The company operates across the US, Europe, and Japan.
SoluSolu Therapeutics is a clinical-stage biotech developing a class of antibody therapeutics that link bifunctional small molecules to proprietary effector antibodies (its CyTAC and TicTAC platforms) to reach cell surface targets like GPCRs and ion channels. Its pipeline targets oncology, immunology and inflammation, and pain, with a lead program in Phase 1 trials for chronic myelomonocytic leukemia.

Companies working in the same space as Trestle Biotherapeutics.

Legal entities · 1

corporate structure
Trestle Biotherapeutics, Inc.

In the news

Trestle named as one of CONNECT San Diego’s “Cool Companies” for 2022 | Trestle Biotherapeuticstrestlebio.com · Apr 2022Trestle Biotherapeuticstrestlebio.com · Feb 2022Trestle Biotherapeutics Funding | <$5 Million Revenue | Complete Analysis | Extruct AIextruct.ai · Jul 2021Trestle Biotherapeutics Backed by Y Combinator | Trestle Biotherapeuticstrestlebio.com · Jan 2021

Frequently asked questions

What does Trestle Biotherapeutics do?
Trestle Biotherapeutics develops bioengineered implantable tissues designed to treat end-stage renal disease, aiming to get patients off dialysis and eventually provide replacement organs. The company uses stem cell biology, biofabrication, and 3D bioprinting technologies to create functional kidney tissue for patients with kidney failure.
Who founded Trestle Biotherapeutics?
Trestle Biotherapeutics was founded by Ben Shepherd, Alice Chen, Alice Chen, PhD in 2020.
Who are Trestle Biotherapeutics's investors?
Trestle Biotherapeutics's investors include Y Combinator, Black Mountain Ventues, C3 Ventures, Draper Associates, Acequia Capital (AceCap), Agrolimen Ventures, Asymmetry Ventures, Axial VC and 4 more.
Where is Trestle Biotherapeutics headquartered?
Trestle Biotherapeutics is headquartered in San Diego, US.